Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Coates A, Regan M, Price K, Debled M, Ejlertsen B, Colleoni M, Gelber R, Thürlimann B, Winer E, Viale G, Gusterson B, Mallon E, Giobbie-Hurder A, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol 2015; 33:2772-9.
27.07.2015Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
27.07.2015J Clin Oncol 2015; 33:2772-9
Metzger Filho Otto, Coates Alan S, Regan Meredith M, Price Karen N, Debled Marc, Ejlertsen Bent, Colleoni Marco, Gelber Richard D, Thürlimann Beat, Winer Eric P, Viale Giuseppe, Gusterson Barry, Mallon Elizabeth, Giobbie-Hurder Anita, Goldhirsch Aron
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gnant M, Dubsky P, Cuzick J, Dowsett M, Forbes J, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386:1341-52.
23.07.2015Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
23.07.2015Lancet 2015; 386:1341-52
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann Beat, van de Velde C, Pan H, Peto R, Davies C, Gnant M, Dubsky P, Cuzick J, Dowsett M, Forbes J F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R C, Gray R
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Aminossadati B, Schmalfeldt B, Burges A, Hillemanns P, Huober J, Wollschlaeger K, Sehouli J, Siffert W, Kuhlmann J, Kimmig R, du Bois A, Meier W, Wimberger P. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol 2015; 80:1139-48.
22.07.2015The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
22.07.2015Br J Clin Pharmacol 2015; 80:1139-48
Bachmann Hagen Sjard, Aminossadati Behnaz, Schmalfeldt Barbara, Burges Alexander, Hillemanns Peter, Huober Jens, Wollschlaeger Kerstin, Sehouli Jalid, Siffert Winfried, Kuhlmann Jan Dominik, Kimmig Rainer, du Bois Andreas, Meier Werner, Wimberger Pauline
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
06.07.2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
06.07.2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 2015; 152:377-87.
25.06.2015Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
25.06.2015Breast Cancer Res Treat 2015; 152:377-87
Loibl Sibylle, Mehta Keyur, Nekljudova Valentina, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hanusch Claus, Hilfrich Jörn, Huober Jens, Schneeweiss Andreas, Kümmel Sherko, Paepke Stefan, Untch Michael, Lederer Bianca, Jackisch Christian, von Minckwitz Gunter
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel) 2015; 10:211-9.
23.06.201514th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
23.06.2015Breast Care (Basel) 2015; 10:211-9
Jackisch Christian, Blohmer Jens-Uwe, Costa Serban-Dan, Decker Thomas, Diel Ingo, Fasching Peter A, Fehm Tanja, Janni Wolfgang, Lück Hans-Joachim, Maass Nicolai, Scharl Anton, Beckmann Matthias W, Loibl Sibylle, Thomssen Christoph, Harbeck Nadia, Huober Jens, von Minckwitz Gunter, Gerber Bernd, Kreipe Hans-Heinrich, Liedtke Cornelia, Marschner Norbert, Möbus Volker, Scheithauer Heike, Schneeweiss Andreas, Untch Michael
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 2015; 10:173-8.
18.06.2015Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
18.06.2015Breast Care (Basel) 2015; 10:173-8
Schramm Amelie, De Gregorio Nikolaus, Widschwendter Peter, Fink Visnja, Huober Jens
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58.
16.06.2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
16.06.2015Lancet Oncol 2015; 16:848-58
Bernhard Jürg, Regan Meredith M, Pagani Olivia, Fleming Gini F, Francis Prudence A, Price Karen N, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Parmar Vani, Pavesi Lorenzo, Puglisi Fabio, Luo Weixiu, Ribi Karin, Colleoni Marco, Burstein Harold J, Tondini Carlo, Pinotti Graziella, Spazzapan Simon, Ruhstaller Thomas, Walley Barbara A
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Frauenheilkd 2015; 75:574-583.
01.06.2015Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
01.06.2015Geburtshilfe Frauenheilkd 2015; 75:574-583
Schneeweiss A, Ruckhäberle E, Huober Jens
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland
Putora P, Stahl M, Schnider A, Mariette C, Van Lanschot J, Jäger R, van der Gaast A, Eisterer W, Budach W, Bedenne L, Ruhstaller T. Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland. Radiat Oncol 2015; 10:116.
21.05.2015Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland
21.05.2015Radiat Oncol 2015; 10:116
Putora Paul Martin, Stahl Michael, Schnider Annelies, Mariette Christophe, Van Lanschot J Jan B, Jäger Robert, van der Gaast Ate, Eisterer Wolfgang, Budach Wilfried, Bedenne Laurent, Ruhstaller Thomas
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26:1533-46.
04.05.2015-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
04.05.2015Ann Oncol 2015; 26:1533-46
Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.
03.05.2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
03.05.2015Breast Cancer Res Treat 2015; 151:373-84
Leyland-Jones Brian, Neven Patrick, Treilleux Isabelle, Rasmussen Birgitte Bruun, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Pagani Olivia, Viale Giuseppe, Rae James M, Harvey Vernon J, Ditzel Henrik J, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Lyng Maria B, Regan Meredith M
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PloS one 2015; 10:e0123435.
17.04.2015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
17.04.2015PloS one 2015; 10:e0123435
Varga Zsuzsanna, Cassoly Estelle, Li Qiyu, Öhlschlegel Christian, Tapia Coya, Lehr Hans Anton, Klingbiel Dirk, Thürlimann Beat, Ruhstaller Thomas
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Zaman K, Rondeau S, Hawle H, Rudolf C, Perey L, Wiliders H, Berset C, Mueller A, Rochlitz C, Hasler-Strub U, Mamot C, Winterhalder R, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer 2015; 51:1212-20.
16.04.2015Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
16.04.2015Eur J Cancer 2015; 51:1212-20
Zaman Khalil, Rondeau Stephanie, Hawle Hanne, Rudolf Christine Biaggi, Perey Lucien, Wiliders Hans, Berset Catherine, Mueller Andreas, Rochlitz Christoph, Hasler-Strub Ursula, Mamot Christoph, Winterhalder Ralph, Neven Patrick
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Hanusch C, Burchardi N, Engels K, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Untch M, Loibl S, Schneeweiss A, von Minckwitz G. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res 2015; 21:2924-31.
30.03.2015Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
30.03.2015Clin Cancer Res 2015; 21:2924-31
Hanusch Claus, Burchardi Nicole, Engels Knut, Blohmer Jens Uwe, Costa Serban, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hilfrich Jörn, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Untch Michael, Loibl Sibylle, Schneeweiss Andreas, von Minckwitz Gunter
Cetuximab induced aseptic meningitis.
Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer A. Cetuximab induced aseptic meningitis. J Clin Neurosci 2015; 22:1061-3.
11.03.2015Cetuximab induced aseptic meningitis.
11.03.2015J Clin Neurosci 2015; 22:1061-3
Ulrich A, Weiler S, Weller M, Rordorf Tamara, Tarnutzer A A
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Erber R, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Liedtke C, Moustafa Z, Gluz O, Brünner N, Kreipe H, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015; 150:279-88.
28.02.2015Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
28.02.2015Breast Cancer Res Treat 2015; 150:279-88
Erber Ramona, Möbus Volker, Augustin Doris, Thomssen Christoph, Jänicke Fritz, Kiechle Marion, Kuhn Walther, Nitz Ulrike, Harbeck Nadia, Liedtke Cornelia, Moustafa Zehra, Gluz Oleg, Brünner Nils, Kreipe Hans Heinrich, Pelz Enrico, Kates Ronald, Bartels Annette, Huober Jens, Mohrmann Svjetlana, Hartmann Arndt
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
27.02.2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
27.02.2015Ann Oncol 2015; 26:873-9
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S